Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03051464 · ClinicalTrials.gov registry record · Phase 2

No Surgery Trial / Two Dose-escalation Strategies

A Phase 2 study of Stage II Rectal Cancer, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.

Recruiting
Registry status
Phase 2
Development phase
131
Enrollment target
4
Study locations

NCT03051464 is a Phase 2 study of Stage II Rectal Cancer that is actively recruiting participants, run by Sir Mortimer B. Davis - Jewish General Hospital. The registered enrollment target is 131 participants. The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03051464, a Phase 2 study of Stage II Rectal Cancer, is actively recruiting participants, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
131 participants
Enrollment target
4
Study locations

Study Summary

A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).

Conditions Studied

Interventions

  • PROCEDURE Complete responders and Non-complete responders
  • RADIATION Chemoradiation + EBRT Boost
  • RADIATION Chemoradiation + HDRBT Boost

Study Locations (4)

Quebec

  • Le Centre Hospitalier de l'Université de Montreal - Montreal
  • Jewish General Hospital - Montreal
  • Centre hospitalier universitaire de Québec - Québec

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2017-04-25
Est. Completion 2030-01
Phase Phase 2

What the Registry Record Tells You About NCT03051464

The ClinicalTrials.gov registry entry for NCT03051464 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stage II Rectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Complete responders and Non-complete responders is the first listed.

NCT03051464 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Quebec, Texas.

Frequently Asked Questions

What is clinical trial NCT03051464 about?

NCT03051464 is a clinical study titled "No Surgery Trial / Two Dose-escalation Strategies". A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with...

What is the current status of trial NCT03051464?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2017-04-25. Estimated completion is 2030-01.

What conditions does trial NCT03051464 study?

This clinical trial studies the following conditions: Stage II Rectal Cancer.

What interventions are being tested in trial NCT03051464?

The interventions under investigation include: Complete responders and Non-complete responders (PROCEDURE), Chemoradiation + EBRT Boost (RADIATION), Chemoradiation + HDRBT Boost (RADIATION).

Who is sponsoring clinical trial NCT03051464?

This trial is sponsored by Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03051464 being conducted?

This trial has 4 study locations across Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage II Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.